Walter M. Stadler, MD
Fred C. Buffett Professor of Medicine
Director, Genitourinary Program
Associate Dean for Clinical Research
University of Chicago
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
Renal cell carcinoma (RCC) is associated with significant morbidity, mortality, and economic burden. This disease accounts for 90% of all kidney cancers (which are the seventh and ninth most common cancers in men and women, respectively), and is associated with a 5-year survival rate of 10% in the case of metastasis. The standard of care for advanced RCC has changed significantly with the development of novel targeting agents. Within the past 4 years, 6 agents have been added to the armamentarium for advanced RCC, leading to revised recommendations, which were based on what little clinical data were available.
RCC is a challenging condition to treat, as many patients demonstrate relative resistance to radiation and chemotherapy, and postsurgical recurrence is a frequent phenomenon. The challenges associated with advanced RCC treatment are compounded by the unrelenting flow of clinical findings and research being published on an annual basis. It is imperative that oncologists be aware of best practices associated with the treatment of advanced RCC in order to achieve optimal outcomes in individuals with advanced RCC. The goal of continuing education activities for oncologists must be to expand their knowledge and competency in best practices related to advanced RCC.
. Target Audience
This educational activity is designed to meet the needs of oncologists and those who manage patients with cancer.
Upon completion of this educational activity, the participant should be able to:
Discuss treatment strategies for advanced RCC
Manage side effects and toxicities related to treatments for advanced RCC
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.
Dr. Stadler Consultant: Novartis, Pfizer/Wyeth, Roche/Genentech, Aveo; Speakers Bureau: Pfizer; Stockholder: Abbott (Spouse).
Office of CME:
Zalman S. Agus, MD has no relevant financial relationships to disclose.
Mila Kostic has no relevant financial relationships to disclose.
Medical Communications Media, Inc.:
Sara Thier, PhD, MPH has no relevant financial relationships to disclose.
Elizabeth Paczolt, MD has no relevant financial relationships to disclose.
Investigational and/or Off-Label Use of Commercial Products and Devices:
The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. In this educational activity, the faculty discusses the investigational use of c-MET inhibitors currently in clinical trials.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and Medical Communications Media, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: October 7, 2011
Last review date: October 7, 2011
Expiration date: October 7, 2012 Commercial Support Statements
Supported by educational grants from Pfizer Inc, AVEO Pharmaceutical, Inc., and Astellas Pharma Global Development, Inc.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 100%
* You are allowed one retake
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
* Windows: Latest release of Safari, Internet Explorer 6/7 or Mozilla/Firefox.
* Macintosh: Latest release of Safari or Mozilla/Firefox.
There is no charge for CME credit.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher,the Perelman School of Medicine at the University of Pennsylvania, or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.